The behavior of α-synuclein in neurons

Movement Disorders

Volumn 25, Issue SUPPL. 1, 2010, Pages

  Fortin, Doris L ^a   Nemani, Venu M ^b   Nakamura, Ken ^b   Edwards, Robert H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

synuclein; Exocytosis; Mobility; Neuron; Parkinson's disease; Synaptic vesicle

Indexed keywords

ALPHA SYNUCLEIN; CALCIUM;

ARTICLE; BLEACHING; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SYNAPSE VESICLE; GENETICS; METABOLISM; MUTATION; NERVE CELL; PATHOLOGY;

ALPHA-SYNUCLEIN; CALCIUM; HUMANS; MUTATION; NEURONS; PARKINSON DISEASE;

EID: 77953409542     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22722     Document Type: Article

References (74)

1. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-108.
2. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
3. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-173.
4. Ibáñez P, Bonnet AM, Débarges B, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364: 1169-1171.
5. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
6. Galvin JE, Uryu K, Lee VM, Trojanowski JQ. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A 1999; 96: 13450-13455.
7. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998; 95: 6469-6473.
8. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
9. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000; 25: 239-252.
10. Cabin DE, Shimazu K, Murphy D, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 2002; 22: 8797-8807.
11. George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995; 15: 361-372.
12. Larsen KE, Schmitz Y, Troyer MD, et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006; 26: 11915-11922.
13. Liu S, Ninan I, Antonova I, et al. alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J. 2004; 23: 4506-4516.
14. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000; 20: 3214-3220.
15. Yavich L, Tanila H, Vepsalainen S, Jakala P. Role of alpha- synuclein in presynaptic dopamine recruitment. J Neurosci 2004; 24: 11165-11170.
16. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988; 8: 2804-2815.
17. Withers GS, George JM, Banker GA, Clayton DF. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res 1997; 99: 87-94.
18. Senior SL, Ninkina N, Deacon R, Bannerman D, Buchman VL, Cragg SJ, Wade-Martins R. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci 2008; 27: 947-957.
19. Iwai A. Properties of NACP/alpha-synuclein and its role in Alzheimer's disease. Biochim Biophys Acta 2000; 1502: 95-109.
20. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 1994; 345: 27-32.
21. Kahle PJ, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci 2000; 20: 6365-6373.
22. Chandra S, Chen X, Rizo J, Jahn R, Sudhof TC. A broken alpha-helix in folded alpha-Synuclein. J Biol Chem 2003; 278: 15313-15318.
23. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998; 273: 9443-9449.
24. Eliezer D, Kutluay E, Bussell R, Jr, Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 2001; 307: 1061-1073.
25. Kubo S, Nemani VM, Chalkley RJ, et al. A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem 2005; 280: 31664-31672.
26. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT, Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996; 35: 13709-13715.
27. Bisaglia M, Trolio A, Bellanda M, Bergantino E, Bubacco L, Mammi S. Structure and topology of the non-amyloid-beta component fragment of human alpha-synuclein bound to micelles: implications for the aggregation process. Protein Sci 2006; 15: 1408-1416.
28. Bussell R, Jr, Eliezer D. A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J Mol Biol 2003; 329: 763-778.
29. Bisaglia M, Schievano E, Caporale A, Peggion E, Mammi S. The 11-mer repeats of human alpha-synuclein in vesicle interactions and lipid composition discrimination: a cooperative role. Biopolymers 2006; 84: 310-316.
30. Kim YS, Laurine E, Woods W, Lee SJ. A novel mechanism of interaction between alpha-synuclein and biological membranes. J Mol Biol 2006; 360: 386-397.
31. Lee HJ, Choi C, Lee SJ. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem. 2002; 277: 671-678.
32. Li J, Uversky VN, Fink AL. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 2001; 40: 11604-11613.
33. Ramakrishnan M, Jensen PH, Marsh D. Alpha-synuclein association with phosphatidylglycerol probed by lipid spin labels. Biochemistry 2003; 42: 12919-12926.
34. Perrin RJ, Woods WS, Clayton DF, George JM. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem 2001; 276: 41958-41962.
35. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003; 37: 583-595.
36. Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, Selkoe DJ. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A 2001; 98: 9110-9115.
37. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 2004; 24: 6715-6723.
38. Rhoades E, Ramlall TF, Webb WW, Eliezer D. Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. Biophys J 2006; 90: 4692-4700.
39. Bussell R, Jr, Eliezer D. Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein. J Biol Chem 2001; 276: 45996-46003.
40. Bussell R, Jr, Eliezer D. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. Biochemistry 2004; 43: 4810-4818.
41. Choi W, Zibaee S, Jakes R, et al. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett 2004; 576: 363-368.
42. Jo E, Fuller N, Rand RP, St George-Hyslop P, Fraser PE. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J Mol Biol 2002; 315: 799-807.
43. Perrin RJ, Woods WS, Clayton DF, George JM. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J Biol Chem 2000; 275: 34393-34398.
44. Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, Nussbaum RL. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem 2002; 277: 6344-6352.
45. Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem 1998; 273: 26292-26294.
46. Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003; 302: 1772-1775.
47. Wislet-Gendebien S, D'Souza C, Kawarai T, et al. Cytosolic proteins regulate alpha-synuclein dissociation from presynaptic membranes. J Biol Chem 2006; 281: 32148-32155.
48. Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH. Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 2005; 25: 10913-10921.
49. Specht CG, Tigaret CM, Rast GF, Thalhammer A, Rudhard Y, Schoepfer R. Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol Cell Neurosci 2005; 28: 326-334.
50. Axelrod D, Koppel DE, Schlessinger J, Elson E, Webb WW. Mobility measurement by analysis of fluorescence photobleaching recovery kinetics. Biophys J 1976; 16: 1055-1069.
51. Lippincott-Schwartz J, Altan-Bonnet N, Patterson GH. Photobleaching and photoactivation: following protein dynamics in living cells. Nat Cell Biol. 2003; suppl: S7-S14.
52. Phair RD, Misteli T. Kinetic modelling approaches to in vivo imaging. Nat Rev Mol Cell Biol 2001; 2: 898-907.
53. Darcy KJ, Staras K, Collinson LM, Goda Y. Constitutive sharing of recycling synaptic vesicles between presynaptic boutons. Nat Neurosci 2006; 9: 315-321.
54. Misteli T. The concept of self-organization in cellular architecture. J Cell Biol 2001; 155: 181-185.
55. Snapp EL, Hegde RS, Francolini M, et al. Formation of stacked ER cisternae by low affinity protein interactions. J Cell Biol 2003; 163: 257-269.
56. Tsuriel S, Geva R, Zamorano P, et al. Local sharing as a predominant determinant of synaptic matrix molecular dynamics. PLoS Biol 2006; 4: e271.
57. Li Z, Murthy VN. Visualizing postendocytic traffic of synaptic vesicles at hippocampal synapses. Neuron 2001; 31: 593-605.
58. Sankaranarayanan S, Ryan TA. Real-time measurements of vesicle-SNARE recycling in synapses of the central nervous system. Nat Cell Biol 2000; 2: 197-204.
59. Geppert M, Sudhof TC. Rab3 and synaptotagmin: the yin and yang of synaptic membrane fusion. Ann Rev Neurosci 1998; 21: 75-95.
60. Chi P, Greengard P, Ryan TA. Synapsin dispersion and reclustering during synaptic activity. Nat Neurosci 2001; 4: 1187-1193.
61. Chi P, Greengard P, Ryan TA. Synaptic vesicle mobilization is regulated by distinct synapsin I phosphorylation pathways at different frequencies. Neuron. 2003; 38: 69-78.
62. Tao-Cheng JH. Activity-related redistribution of presynaptic proteins at the active zone. Neuroscience 2006; 141: 1217-1224.
63. Fink AL. The aggregation and fibrillation of alpha-synuclein. Acc Chem Res 2006; 39: 628-634.
64. Uversky VN, Fink AL. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta 2004; 1698: 131-153.
65. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 2001; 276: 10737-10744.
66. Volles MJ, Lansbury PT, Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002; 41: 4595-4602.
67. Volles MJ, Lansbury PT, Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003; 42: 7871-7878.
68. Volles MJ, Lee SJ, Rochet JC, et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001; 40: 7812-7819.
69. Murray D, Arbuzova A, Honig B, McLaughlin S. The role of electrostatic and nonpolar interactions in the association of peripheral proteins with membranes. In: Simon S, McIntosh T, editor. Current Topics in Membranes. Vol. 52. San Diego, CA: Academic Press; 2002. p 277-298.
70. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999; 274: 19509-19512.
71. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998; 4: 1318-1320.
72. Zhu M, Fink AL. Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem 2003; 278: 16873-16877.
73. Narayanan V, Scarlata S. Membrane binding and self-association of alpha-synucleins. Biochemistry 2001; 40: 9927-9934.
74. Roberti MJ, Bertoncini CW, Klement R, Jares-Erijman EA, Jovin TM. Fluorescence imaging of amyloid formation in living cells by a functional, tetracysteine-tagged alpha-synuclein. Nat Methods 2007; 4: 345-351.